Ticker > Company >

Emcure Pharma share price

Emcure Pharmaceuticals Ltd.

NSE: EMCURE BSE: 544210 SECTOR: Pharmaceuticals & Drugs  49k   27   11

1442.75
+17.85 (1.25%)
BSE: 26 Dec 04:01 PM

Price Summary

Today's High

₹ 1463.9

Today's Low

₹ 1420.85

52 Week High

₹ 1577.5

52 Week Low

₹ 1226.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

27330.28 Cr.

Enterprise Value

28702.78 Cr.

No. of Shares

18.94 Cr.

P/E

169.93

P/B

9.66

Face Value

₹ 10

Div. Yield

0.21 %

Book Value (TTM)

₹  149.32

CASH

32.12 Cr.

DEBT

1404.62 Cr.

Promoter Holding

78.08 %

EPS (TTM)

₹  8.49

Sales Growth

12.57%

ROE

8.59 %

ROCE

10.7%

Profit Growth

0.48 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year12.57%
3 Year3.51%
5 Year7.35%

Profit Growth

1 Year0.48%
3 Year-27.41%
5 Year-10.73%

ROE%

1 Year8.59%
3 Year13.36%
5 Year13.96%

ROCE %

1 Year10.7%
3 Year14.35%
5 Year14.87%

Debt/Equity

0.732

Price to Cash Flow

46.72

Interest Cover Ratio

2.2036

CFO/PAT (5 Yr. Avg.)

1.96435861571219

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 78.08 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -36.0651 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.96435861571219.
  • The company has a high promoter holding of 78.08%.

 Limitations

  • The company has shown a poor profit growth of -27.4095935761488% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.51112605577903% for the Past 3 years.
  • The company is trading at a high EV/EBITDA of 48.1571.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024
Net Sales 970.29 1104.63
Total Expenditure 855.11 952.47
Operating Profit 115.19 152.16
Other Income 32.51 54.93
Interest 37.57 31.4
Depreciation 55.08 56.34
Exceptional Items 0 0
Profit Before Tax 55.05 119.36
Tax 14.6 32.44
Profit After Tax 40.45 86.92
Adjusted EPS (Rs) 2.23 4.6

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 2375.71 3153.66 3387.24 3107.09 3497.66
Total Expenditure 1952.29 2410.26 2592.57 2668.59 3055.76
Operating Profit 423.42 743.41 794.67 438.49 441.89
Other Income 137.62 111.91 132.68 125.35 138.26
Interest 137.22 123.34 145.14 166.83 166.09
Depreciation 154.97 156.24 165.79 178.52 204.83
Exceptional Items -44.16 -18.29 0 -6.15 -9.32
Profit Before Tax 224.68 557.45 616.42 212.34 199.91
Tax 49.48 136.97 169.61 52.28 39.08
Net Profit 175.21 420.48 446.81 160.06 160.83
Adjusted EPS (Rs.) 9.69 23.25 24.71 8.85 8.88

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 180.85 180.85 180.85 180.85 181.15
Total Reserves 1733.7 2120.92 1531.68 1661.02 1753.95
Borrowings 453.87 645.97 512.4 600.65 438.21
Other N/C liabilities 123 126.27 164.19 177 253.51
Current liabilities 1379.78 1789.18 1934.06 1996.33 2130.12
Total Liabilities 3871.2 4863.2 4323.18 4615.85 4756.93
Assets
Net Block 1166.06 1277.9 1307.36 1432.71 1718.24
Capital WIP 326.06 192.09 239.25 253.1 106.4
Intangible WIP 0 0 0 0 0
Investments 407.71 863.73 563.36 690.02 684
Loans & Advances 138.23 299.42 63.25 77.51 105.37
Other N/C Assets 25.58 14.6 13.92 23.01 24.91
Current Assets 1807.57 2215.46 2136.05 2139.51 2118.01
Total Assets 3871.2 4863.2 4323.18 4615.85 4756.93
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 224.68 557.45 616.42 212.34 199.91
Adjustment 261.78 246.72 265 309.21 325.56
Changes in Assets & Liabilities -70.5 84.38 -283.04 68.37 126.36
Tax Paid -30.71 -113.67 -170.67 -84.54 -66.86
Operating Cash Flow 385.25 774.87 427.71 505.37 584.97
Investing Cash Flow -168.94 -835.78 -393.81 -270.56 -173.08
Financing Cash Flow -45.87 30.97 -342.96 -54.52 -287.75
Net Cash Flow 170.45 -29.94 -309.06 180.3 124.15

Corporate Actions

Investors Details

PARTICULARS Sep 2024%
promoters 78.08
bhavana satish mehta 4.72
everest trust (shares hel... 7.68
girish harrai desai 0.06
kamini sunil mehta 0.88
namita vikas thapar 2.68
niraj sunil mehta 0.58
pushpa rajnikant mehta 2.06
ranjanakumari mukeshbhai ... 0.02
rutav sunil mehta 0.52
samit s mehta 7.16
sanjay rajanikant mehta 1.96
satish r mehta 39.87
shaila sharad gujar 0.04
smita paresh shah 0.07
suhasinee saumil shah 0.07
sunil rajanikant mehta 1.51
surekha umakant shah 0.17
swati hetalkumar shah 0.03
unity trust (shares held ... 7.67
vikas m thapar 0.34
PARTICULARS Sep 2024%
investors 21.92
bc investments iv limited... 8.69

Annual Reports

No Annual reports exist for this company.Report us

Ratings & Research Reports

Company Presentations

Emcure Pharma Stock Price Analysis and Quick Research Report. Is Emcure Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Emcure Pharma and its performance over the period of time. Emcure Pharma stock price today is Rs 1444.35.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Emcure Pharma cash from the operating activity was Rs 584.973 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Emcure Pharma has a Debt to Equity ratio of 0.732 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Emcure Pharma , the EPS growth was 0.3164 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Emcure Pharma has OPM of 12.6340076422632 % which is a bad sign for profitability.
     
  • ROE: Emcure Pharma have a poor ROE of 8.59 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Emcure Pharma is Rs 1444.35. One can use valuation calculators of ticker to know if Emcure Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Emcure Pharma
X